[Press release] Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease

17/02/20

DOWNLOAD

[Congress] EMIM 24-27 March 2020 – Thessaloniki – Greece

[Congress] EMIM - 24-27 March 2020 – Thessaloniki –  Greece

Meet Cyril Berthet, Pharmaco-imaging Unit Director, at EMIM!

It takes 2 to tango: compound labeling and complementary imaging approaches to show how your compound works & targets the right patient.  

Through pharmaco-imaging, the results of preclinical studies can influence the early decision to continue or interrupt the development of a drug candidate. In the clinical development phase, imaging offers an exceptional opportunity to follow the drug in humans with the same techniques developed during the preclinical phase. Novel therapies are converging towards precision medicine, for which pharmaco-imaging is indispensable to all players in the drug development cycle – from the pharmaceutical industry to clinicians – to ensure that the most appropriate treatments are being matched to the needs of the patient.

Explore our multi-modal pharmaco-imaging & targeted radiotherapy expertise for your preclinical projects:

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational nuclear medicine biomarkers
  • Evaluation of targeted radiotherapy efficacy

I fix a meeting

[Congress] Keystone Symposium : Advances in Cancer Immunotherapy – 22-26 March - Fairmont Chateau Whistler – Canada

[Congress] - Keystone Symposium : Advances in Cancer Immunotherapy – 22-26 March - Fairmont Chateau Whistler - Canada

Our experts Jill Rocchetti and Carol Gebert will be present!

Supporting your immuno-onco drug discovery programs from hit identification to candidate selection!

The use of immunotherapies in oncology has drastically changed the way of treating cancer, providing innovative and efficient therapeutic solutions. Currently, tremendous R&D efforts are done in immuno-oncology to discover new targets and develop new drugs.

In that context, the use of relevant and robust assays to predict therapeutic efficiencies has become a key for drug discovery programs.

Oncodesign develops a broad range of solutions to support your drug discovery projects in immuno-oncology.

We can provide solutions on a stand-alone basis or through an integrated drug discovery package - from hit identification to candidate selection.

Based on human immune material for in vitro/ex vivo phenotypic assays and on advanced preclinical models – syngeneic or humanized - for in vivo assays, our scientists help you to assess your compound efficiency in routine or customized assays.

I fix a meeting

[Congress] I/O Summit – 9-12 March – London

[Congress] I/O Summit – 9-12 March – London

Comprehensive solution to predict your drug efficacy in immuno-oncology

Immunological cell death (ICD) is a form of cancer cell death induced by radiotherapy, photodynamic therapy and chemotherapeutic agents.
Unlike apoptosis or necrosis, ICD can induce an effective immune response directed against the tumor whereby both dendritic cells and T lymphocytes are mediators of this response.
Dying cancer cells recruit and activate immune cells by releasing damage-associated molecular patterns (DAMPs).

Come & listen to Jean-François Mirjolet depicting our innovation solution for ICD.

[Talk] Immunogenic cell death, a novel screening platform integrating tumor cells and immune cells co-culture assays

[When] Tuesday 10th March -  9:40-10:10  -  Immunomodulatory Approaches stream

%MCEPASTEBIN%

I fix a meeting

%MCEPASTEBIN%

By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.